Nonsense Suppression Therapy: An Emerging Treatment for Hereditary Skin Diseases
DOI:
https://doi.org/10.2340/actadv.v102.353Keywords:
readthrough, aminoglycosides, PTC124, nonsense-mediated decay, suppressor tRNA, hereditary skin diseasesAbstract
Nonsense mutations cause the premature termination of protein translation via premature termination codons (PTCs), leading to the synthesis of incomplete functional proteins and causing large numbers of genetic disorders. The emergence of nonsense suppression therapy is considered to be an effective method for the treatment of hereditary diseases, but its application in hereditary skin diseases is relatively limited. This review summarizes the current research status of nonsense suppression therapy for hereditary skin diseases, and discusses the potential opportunities and challenges of applying new technologies related to nonsense suppression therapy to dermatology. Further research is needed into the possible use of nonsense suppression therapy as a strategy for the safer and specific treatment of hereditary skin diseases.
Downloads
References
Porter JJ, Heil CS, Lueck JD. Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip Rev RNA 2021; 12: e1641.
https://doi.org/10.1002/wrna.1641 DOI: https://doi.org/10.1002/wrna.1641
Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001; 107: 411-414.
https://doi.org/10.1016/S0092-8674(01)00583-9 DOI: https://doi.org/10.1016/S0092-8674(01)00583-9
Baradaran-Heravi A, Balgi AD, Hosseini-Farahabadi S, Choi K, Has C, Roberge M. Effect of small molecule eRF3 degraders on premature termination codon readthrough. Nucleic Acids Res 2021; 49: 3692-3708.
https://doi.org/10.1093/nar/gkab194 DOI: https://doi.org/10.1093/nar/gkab194
Lee HL, Dougherty JP. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 2012; 136: 227-266.
https://doi.org/10.1016/j.pharmthera.2012.07.007 DOI: https://doi.org/10.1016/j.pharmthera.2012.07.007
Panchal RG, Wang S, McDermott J, Link CJ. Partial functional correction of xeroderma pigmentosum group A cells by suppressor tRNA. Hum Gene Ther 1999; 10: 2209-2219.
https://doi.org/10.1089/10430349950017194 DOI: https://doi.org/10.1089/10430349950017194
Frolova L, Le Goff X, Rasmussen HH, Cheperegin S, Drugeon G, Kress M, et al. A highly conserved eukaryotic protein family possessing properties of polypeptide chain release factor. Nature 1994; 372: 701-703.
https://doi.org/10.1038/372701a0 DOI: https://doi.org/10.1038/372701a0
Temple GF, Dozy AM, Roy KL, Kan YW. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia. Nature 1982; 296: 537-540.
https://doi.org/10.1038/296537a0 DOI: https://doi.org/10.1038/296537a0
Kiselev AV, Ostapenko OV, Rogozhkina EV, Kholod NS, Seit NA, Baranov AN, et al. Suppression of nonsense mutations in the Dystrophin gene by a suppressor tRNA gene. Mol Biol (Mosk) 2002; 36: 43-47.
https://doi.org/10.1023/A:1014238221426 DOI: https://doi.org/10.1023/A:1014238221426
Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-469.
https://doi.org/10.1038/nm0496-467 DOI: https://doi.org/10.1038/nm0496-467
Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683-1692.
https://doi.org/10.1164/ajrccm.163.7.2004001 DOI: https://doi.org/10.1164/ajrccm.163.7.2004001
Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000; 48: 164-169.
https://doi.org/10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B DOI: https://doi.org/10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B
Sossi V, Giuli A, Vitali T, Tiziano F, Mirabella M, Antonelli A, et al. Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. Eur J Hum Genet 2001; 9: 113-120.
https://doi.org/10.1038/sj.ejhg.5200599 DOI: https://doi.org/10.1038/sj.ejhg.5200599
Kaler SG, Tang J, Donsante A, Kaneski CR. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol 2009; 65: 108-113.
https://doi.org/10.1002/ana.21576 DOI: https://doi.org/10.1002/ana.21576
Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004; 101: 15676-15681.
https://doi.org/10.1073/pnas.0405155101 DOI: https://doi.org/10.1073/pnas.0405155101
Fazzari M, Frasca A, Bifari F, Landsberger N. Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity. Rna Biol 2019; 16: 1414-1423.
https://doi.org/10.1080/15476286.2019.1632633 DOI: https://doi.org/10.1080/15476286.2019.1632633
Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001; 10: 291-299.
https://doi.org/10.1093/hmg/10.3.291 DOI: https://doi.org/10.1093/hmg/10.3.291
Helip-Wooley A, Park MA, Lemons RM, Thoene JG. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002; 75: 128-133.
https://doi.org/10.1006/mgme.2001.3272 DOI: https://doi.org/10.1006/mgme.2001.3272
Sangkuhl K, Schulz A, Rompler H, Yun J, Wess J, Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004; 13: 893-903.
https://doi.org/10.1093/hmg/ddh105 DOI: https://doi.org/10.1093/hmg/ddh105
Grayson C, Chapple JP, Willison KR, Webster AR, Hardcastle AJ, Cheetham ME. In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J Med Genet 2002; 39: 62-67.
https://doi.org/10.1136/jmg.39.1.62 DOI: https://doi.org/10.1136/jmg.39.1.62
Moosajee M, Tracey-White D, Smart M, Weetall M, Torriano S, Kalatzis V, et al. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. Hum Mol Genet 2016; 25: 3416-3431.
https://doi.org/10.1093/hmg/ddw184 DOI: https://doi.org/10.1093/hmg/ddw184
Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY. Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet 2008; 17: 3987-4000.
https://doi.org/10.1093/hmg/ddn302 DOI: https://doi.org/10.1093/hmg/ddn302
Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet 2007; 122: 373-381.
https://doi.org/10.1007/s00439-007-0410-7 DOI: https://doi.org/10.1007/s00439-007-0410-7
Nishimoto K, Iijima K, Shirakawa T, Kitagawa K, Satomura K, Nakamura H, et al. PAX2 gene mutation in a family with isolated renal hypoplasia. J Am Soc Nephrol 2001; 12: 1769-1772.
https://doi.org/10.1681/ASN.V1281769 DOI: https://doi.org/10.1681/ASN.V1281769
Richardson R, Smart M, Tracey-White D, Webster AR, Moosajee M. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Exp Eye Res 2017; 155: 24-37.
https://doi.org/10.1016/j.exer.2017.01.001 DOI: https://doi.org/10.1016/j.exer.2017.01.001
Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, et al. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet 2011; 43: 306-308.
https://doi.org/10.1038/ng.778 DOI: https://doi.org/10.1038/ng.778
Castaman G, Bertoncello K, Bernardi M, Eikenboom JC, Budde U, Rodeghiero F. Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation. Am J Hematol 2007; 82: 376-380.
https://doi.org/10.1002/ajh.20803 DOI: https://doi.org/10.1002/ajh.20803
Bezzerri V, Cipolli M. Shwachman-Diamond syndrome: molecular mechanisms and current perspectives. Mol Diagn Ther 2019; 23: 281-290.
https://doi.org/10.1007/s40291-018-0368-2 DOI: https://doi.org/10.1007/s40291-018-0368-2
Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ, et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther 1996; 3: 797-801.
Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med 2016; 6: a027029.
https://doi.org/10.1101/cshperspect.a027029 DOI: https://doi.org/10.1101/cshperspect.a027029
Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol 2012; 47: 444-463.
https://doi.org/10.3109/10409238.2012.694846 DOI: https://doi.org/10.3109/10409238.2012.694846
Schueren F, Thoms S. Functional translational readthrough: a systems biology perspective. Plos Genet 2016; 12: e1006196.
https://doi.org/10.1371/journal.pgen.1006196 DOI: https://doi.org/10.1371/journal.pgen.1006196
Leier A, Bedwell DM, Chen AT, Dickson G, Keeling KM, Kesterson RA, et al. Mutation-directed therapeutics for neurofibromatosis Type I. Mol Ther Nucleic Acids 2020; 20: 739-753.
https://doi.org/10.1016/j.omtn.2020.04.012 DOI: https://doi.org/10.1016/j.omtn.2020.04.012
McHugh DR, Cotton CU, Hodges CA. Synergy between readthrough and nonsense mediated decay inhibition in a murine model of cystic fibrosis nonsense mutations. Int J Mol Sci 2020; 22: 344.
https://doi.org/10.3390/ijms22010344 DOI: https://doi.org/10.3390/ijms22010344
Prokhorova I, Altman RB, Djumagulov M, Shrestha JP, Urzhumtsev A, Ferguson A, et al. Aminoglycoside interactions and impacts on the eukaryotic ribosome. Proc Natl Acad Sci U S A 2017; 114: e10899-e10908.
https://doi.org/10.1073/pnas.1715501114 DOI: https://doi.org/10.1073/pnas.1715501114
Baradaran-Heravi A, Niesser J, Balgi AD, Choi K, Zimmerman C, South AP, et al. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proc Natl Acad Sci U S A 2017; 114: 3479-3484.
https://doi.org/10.1073/pnas.1620982114 DOI: https://doi.org/10.1073/pnas.1620982114
Pasmooij A. Topical gentamicin for the treatment of genetic skin diseases. J Invest Dermatol 2018; 138: 731-734.
https://doi.org/10.1016/j.jid.2017.12.008 DOI: https://doi.org/10.1016/j.jid.2017.12.008
Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008; 24: 552-563.
https://doi.org/10.1016/j.tig.2008.08.010 DOI: https://doi.org/10.1016/j.tig.2008.08.010
Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E. Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons. Mol Med 2018; 24: 25.
https://doi.org/10.1186/s10020-018-0024-7 DOI: https://doi.org/10.1186/s10020-018-0024-7
Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009; 52: 2836-2845.
https://doi.org/10.1021/jm801640k DOI: https://doi.org/10.1021/jm801640k
Hainrichson M, Nudelman I, Baasov T. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem 2008; 6: 227-239.
https://doi.org/10.1039/B712690P DOI: https://doi.org/10.1039/B712690P
Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47: 430-444.
https://doi.org/10.1177/0091270006297140 DOI: https://doi.org/10.1177/0091270006297140
Campofelice A, Lentini L, Di Leonardo A, Melfi R, Tutone M, Pace A, et al. Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs). Int J Mol Sci 2019; 20: 3329.
https://doi.org/10.3390/ijms20133329 DOI: https://doi.org/10.3390/ijms20133329
Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008; 105: 2064-2069.
https://doi.org/10.1073/pnas.0711795105 DOI: https://doi.org/10.1073/pnas.0711795105
Lentini L, Melfi R, Di Leonardo A, Spinello A, Barone G, Pace A, et al. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol Pharm 2014; 11: 653-664.
https://doi.org/10.1021/mp400230s DOI: https://doi.org/10.1021/mp400230s
Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A 2016; 113: 12508-12513.
https://doi.org/10.1073/pnas.1605336113 DOI: https://doi.org/10.1073/pnas.1605336113
McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. Plos Biol 2013; 11: e1001593.
https://doi.org/10.1371/journal.pbio.1001593 DOI: https://doi.org/10.1371/journal.pbio.1001593
Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 2009; 206: 2285-2297.
https://doi.org/10.1084/jem.20081940 DOI: https://doi.org/10.1084/jem.20081940
Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet 2012; 21: 4007-4020.
https://doi.org/10.1093/hmg/dds223 DOI: https://doi.org/10.1093/hmg/dds223
Du L, Jung ME, Damoiseaux R, Completo G, Fike F, Ku JM, et al. A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther 2013; 21: 1653-1660.
https://doi.org/10.1038/mt.2013.150 DOI: https://doi.org/10.1038/mt.2013.150
Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA 2017; 23: 567-577.
https://doi.org/10.1261/rna.060236.116 DOI: https://doi.org/10.1261/rna.060236.116
Arakawa M, Shiozuka M, Nakayama Y, Hara T, Hamada M, Kondo S, et al. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 2003; 134: 751-758.
https://doi.org/10.1093/jb/mvg203 DOI: https://doi.org/10.1093/jb/mvg203
Thompson J, Pratt CA, Dahlberg AE. Effects of a number of classes of 50S inhibitors on stop codon readthrough during protein synthesis. Antimicrob Agents Chemother 2004; 48: 4889-4891.
https://doi.org/10.1128/AAC.48.12.4889-4891.2004 DOI: https://doi.org/10.1128/AAC.48.12.4889-4891.2004
Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol 2015; 16: 665-677.
https://doi.org/10.1038/nrm4063 DOI: https://doi.org/10.1038/nrm4063
Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol 2009; 16: 107-113.
https://doi.org/10.1038/nsmb.1550 DOI: https://doi.org/10.1038/nsmb.1550
Azzalin CM, Lingner J. The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr Biol 2006; 16: 433-439.
https://doi.org/10.1016/j.cub.2006.01.018 DOI: https://doi.org/10.1016/j.cub.2006.01.018
Lueck JD, Yoon JS, Perales-Puchalt A, Mackey AL, Infield DT, Behlke MA, et al. Engineered transfer RNAs for suppression of premature termination codons. Nat Commun 2019; 10: 822.
https://doi.org/10.1038/s41467-019-08329-4 DOI: https://doi.org/10.1038/s41467-019-08329-4
Buvoli M, Buvoli A, Leinwand LA. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. Mol Cell Biol 2000; 20: 3116-3124.
https://doi.org/10.1128/MCB.20.9.3116-3124.2000 DOI: https://doi.org/10.1128/MCB.20.9.3116-3124.2000
Zhou Y, Jiang Q, Takahagi S, Shao C, Uitto J. Premature termination codon read-through in the ABCC6 gene: potential treatment for pseudoxanthoma elasticum. J Invest Dermatol 2013; 133: 2672-2677.
https://doi.org/10.1038/jid.2013.234 DOI: https://doi.org/10.1038/jid.2013.234
Ohguchi Y, Nomura T, Suzuki S, Takeda M, Miyauchi T, Mizuno O, et al. Gentamicin-induced readthrough and nonsense-mediated mRNA decay of SERPINB7 nonsense mutant transcripts. J Invest Dermatol 2018; 138: 836-843.
https://doi.org/10.1016/j.jid.2017.10.014 DOI: https://doi.org/10.1016/j.jid.2017.10.014
Li Y, Yu X, Pan C, Wang Y, Han J, Yao Z, et al. Effect of gentamicin ointment in patients with nagashima-type palmoplantar keratosis: a double-blind vehicle-controlled study. Acta Derm Venereol 2021; 101: adv00392.
https://doi.org/10.2340/00015555-3760 DOI: https://doi.org/10.2340/00015555-3760
Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Invest 2017; 127: 3028-3038.
https://doi.org/10.1172/JCI92707 DOI: https://doi.org/10.1172/JCI92707
Atanasova VS, Jiang Q, Prisco M, Gruber C, Pinon HJ, Chen M, et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length Type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2017; 137: 1842-1849.
https://doi.org/10.1016/j.jid.2017.05.011 DOI: https://doi.org/10.1016/j.jid.2017.05.011
Cogan J, Weinstein J, Wang X, Hou Y, Martin S, South AP, et al. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther 2014; 22: 1741-1752.
https://doi.org/10.1038/mt.2014.140 DOI: https://doi.org/10.1038/mt.2014.140
Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 2006; 126: 229-231.
https://doi.org/10.1038/sj.jid.5700031 DOI: https://doi.org/10.1038/sj.jid.5700031
Kuschal C, DiGiovanna JJ, Khan SG, Gatti RA, Kraemer KH. Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci U S A 2013; 110: 19483-19488.
https://doi.org/10.1073/pnas.1312088110 DOI: https://doi.org/10.1073/pnas.1312088110
Satokata I, Tanaka K, Okada Y. Molecular basis of group A xeroderma pigmentosum: a missense mutation and two deletions located in a zinc finger consensus sequence of the XPAC gene. Hum Genet 1992; 88: 603-607.
https://doi.org/10.1007/BF02265282 DOI: https://doi.org/10.1007/BF02265282
Peled A, Samuelov L, Sarig O, Bochner R, Malki L, Pavlovsky M, et al. Treatment of hereditary hypotrichosis simplex of the scalp with topical gentamicin. Br J Dermatol 2020; 183: 114-120.
https://doi.org/10.1111/bjd.18718 DOI: https://doi.org/10.1111/bjd.18718
Morais P, Adachi H, Yu YT. Suppression of nonsense mutations by new emerging technologies. Int J Mol Sci 2020; 21: 4394.
https://doi.org/10.3390/ijms21124394 DOI: https://doi.org/10.3390/ijms21124394
Published
How to Cite
License
Copyright (c) 2022 Jiangfan Yu, Bingsi Tang, Xinglan He, Puyu Zou, Zhuotong Zeng, Rong Xiao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
All published articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
